1. Review recent studies that have changed standard therapy for locally advanced gastroesophageal cancer including chemotherapy and immunotherapy
2. Review ongoing clinical trials and their rationale attempting to improve clinical outcomes and/or treatment tolerability, including pharmacogenomically directed therapy
3. Review understanding of ctDNA minimal residual disease as a prognostic biomarker, and current limitations as a predictive biomarker of therapeutic benefit.
08/09/2021 - 12:00pm to 1:00pm CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Daniel Catenacci, MD